Cencora (COR) Revenue — Quarter Ended Sep 30, 2025
Revenue increased in the reporting quarter. The growth was observed both sequentially and compared to the same period last year.
Key takeaway
Quarter ended Sep 30, 2025 · FY2025 Q4
Revenue increased in the reporting quarter. The growth was observed both sequentially and compared to the same period last year.
Financial snapshot
Reported revenue, sequential change, year-over-year change, and trailing four-quarter revenue.
Quarter revenue
$83.7B
Revenue reported for this quarter.
Quarter-over-quarter
+3.8%
Change from the immediately preceding quarter.
Year-over-year
+5.9%
Change from the comparable year-ago quarter.
Trailing four quarters
$321.3B
Sum of the latest four reported quarters.
Quarterly revenue trend
The latest four reported quarters with year-over-year comparisons.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Dec 31, 2024 | $81.5B | +12.8% |
| Mar 31, 2025 | $75.5B | +10.3% |
| Jun 30, 2025 | $80.7B | +8.7% |
| Sep 30, 2025 | $83.7B | +5.9% |
Revenue performance
Revenue for the quarter was higher, reflecting the company's role as a global pharmaceutical sourcing and distribution services company.
Quarterly comparison
Compared to the immediately preceding quarter, revenue grew. Compared to the same quarter one year earlier, revenue also increased.
What to watch
The company has opioid litigation payment obligations extending over the next 13 years, which may affect future cash flows.